Drug discovery group encouraged by trials progress
Drug discovery group Evgen Pharma said it was delighted by progress on treatments under development when it announced its interim results for the six months to September 30 today.
The AIM-listed business, which has offices in Wilmslow and Liverpool Science Park, focuses on treatments for cancer, strokes and Multiple Sclerosis.
It said it released positive interim data from its ongoing clinical study involving its SFX-01 product for the treatment and evaluation of metastatic breast cancer.
The company's financial performance w... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...